We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Eli Lilly ( LLY 1.21%) and Novo Nordisk ( NVO 2.66%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares soared over 14% ...

With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY ... Lilly’s shares jumped 3.4% on Feb. 6 after the company reported Q4 2024 adjusted EPS of $5.32 and revenue of $13.5 billion ...